Justin Honaman, head of worldwide retail and consumer goods go-to-market at Amazon Web Services, tells this week’s Video Forum about how generative artificial intelligence will alter the retail and CPG industries. Among the topics Honaman addresses are the distinctions between artificial intelligence, machine learning and generative AI; how the new technology fits in with traditional data analytics capabilities; and potential use cases.
Video Forum: Justin Honaman, Amazon Web Services
Justin Honaman, head of worldwide retail and consumer goods go-to-market at Amazon Web Services, tells this week’s Video Forum about how generative artificial intelligence will alter the retail and CPG industries.
Related
Kroger-Albertsons merger goes on trial in an Oregon federal court
The FTC faces off against lawyers from Albertsons and Kroger in a fight over competition in the grocery channel.
FDA approves Moderna’s updated COVID-19 vaccine
Moderna's updated COVID-19 vaccine targets the KP.2 variant of SARS-CoV-2 to help prevent COVID-19 in individuals 6 months of age and older.
Kroger sues FTC, claims merger challenge violates Constitution
The company argues that by proceeding in its administrative tribunal, in addition to the separate action in federal court, the FTC is violating Constitutional protections.
CRN to Federal Appeals Court: NY AG’s arguments don’t support denial of preliminary injunction in NY age restrictions case
CRN’s most recent brief argues that the NY AG does not meaningfully address CRN’s arguments about the Act’s constitutional infirmities.
Latest
Senate finance leaders introduce bipartisan PBM Reform, NACDS hails move and calls for swift passage
Legislation aims to curtail harmful PBM middlemen tactics that inflate drug costs and force pharmacies to close.
NCPA urges Congress to pass Crapo-Wyden PBM Reforms
Wide bipartisan support means no more excuses, says NCPA.
Kroger Q3 earnings beat estimates
Gains in eCommerce and private-label brands offset charges tied to automated fulfillment network; grocer lifts earnings guidance for the year.
CVS Health to pay $37.76 million over insulin pen overbilling allegations
Settlement resolves decade-long False Claims Act violations tied to premature refills and inaccurate reporting to federal health care programs.